These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10371553)

  • 1. A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in HIV-associated cognitive impairment.
    Di Rocco A
    Neurology; 1999 Jun; 52(9):1920; author reply 1920-1. PubMed ID: 10371553
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in HIV-associated cognitive impairment.
    Roesler R; Quevedo J; Walz R; Bianchin M
    Neurology; 1999 Jun; 52(9):1920-1. PubMed ID: 10371554
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.
    Neurology; 1998 Mar; 50(3):645-51. PubMed ID: 9521250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.
    Sacktor N; Schifitto G; McDermott MP; Marder K; McArthur JC; Kieburtz K
    Neurology; 2000 Jan; 54(1):233-5. PubMed ID: 10636157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
    Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal selegiline (Emsam).
    Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
    [No Abstract]   [Full Text] [Related]  

  • 7. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

  • 9. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
    LeWitt PA
    Clin Neuropharmacol; 2007; 30(5):305-7. PubMed ID: 17909310
    [No Abstract]   [Full Text] [Related]  

  • 10. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness and tolerability of selegiline in the treatment of pathological cerebral involutions].
    Bettini R; Gorini M
    Clin Ter; 2002; 153(6):377-80. PubMed ID: 12645393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose selegiline (L-Deprenyl) in social phobia.
    Simpson HB; Schneier FR; Marshall RD; Campeas RB; Vermes D; Silvestre J; Davies S; Liebowitz MR
    Depress Anxiety; 1998; 7(3):126-9. PubMed ID: 9656093
    [No Abstract]   [Full Text] [Related]  

  • 13. L-deprenyl in Alzheimer's disease: cognitive and behavioral effects.
    Freedman M; Rewilak D; Xerri T; Cohen S; Gordon AS; Shandling M; Logan AG
    Neurology; 1998 Mar; 50(3):660-8. PubMed ID: 9521253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis.
    Magis D; Ambrosini A; Sándor P; Jacquy J; Laloux P; Schoenen J
    Headache; 2007 Jan; 47(1):52-7. PubMed ID: 17355494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-deprenyl and physostigmine for the treatment of Alzheimer's disease.
    Marin DB; Bierer LM; Lawlor BA; Ryan TM; Jacobson R; Schmeidler J; Mohs RC; Davis KL
    Psychiatry Res; 1995 Oct; 58(3):181-9. PubMed ID: 8570774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of high-dose α-lipoic acid in the treatment of diabetic polyneuropathy].
    Gu XM; Zhang SS; Wu JC; Tang ZY; Lu ZQ; Li H; Liu C; Chen L; Ning G
    Zhonghua Yi Xue Za Zhi; 2010 Sep; 90(35):2473-6. PubMed ID: 21092474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selegiline in ADHD adults: plasma monoamines and monoamine metabolites.
    Ernst M; Liebenauer LL; Tebeka D; Jons PH; Eisenhofer G; Murphy DL; Zametkin AJ
    Neuropsychopharmacology; 1997 Apr; 16(4):276-84. PubMed ID: 9094145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study.
    Jungerman T; Rabinowitz D; Klein E
    J Clin Psychopharmacol; 1999 Dec; 19(6):522-5. PubMed ID: 10587287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.